All the news Showing 10 of 20 articles from: Side effectsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Why do people with HIV delay hepatitis C treatment? Keith Alcorn / 15 July 2022 Greater efforts by healthcare providers to build trusting relationships with people with HIV and hepatitis C, together with a greater focus on overcoming concerns about treatment side effects, are likely to be needed ... Weight gain after hepatitis C cure is common Keith Alcorn / 19 May 2020 Substantial weight gain is common after hepatitis C cure, an analysis of a large cohort shows, and around one in five people with normal body weight became overweight within two years, US ... Faecal transplants improve encephalopathy in people with advanced liver disease Liz Highleyman / 24 April 2019 Faecal microbiota transplantation (FMT), which helps restore a healthy mix of bacteria in the gut, can help reverse brain function impairment in people with liver failure, according to a report at the International ... Parkinson's disease more common in people with viral hepatitis Keith Alcorn / 05 April 2017 Parkinson’s disease is more common among people with hepatitis B or C than in the general population in England, a cohort study that looked back from 1999 to 2011 has ... Cardiovascular disease risk is higher for people with hepatitis C Keith Alcorn / 20 January 2016 People with hepatitis C are at higher risk of dying from cardiovascular disease, suffering a stroke or developing cardiovascular problems than people with similar risk factors for heart disease who ... Rare life-threatening toxicities emerge as real-world use of hepatitis C drugs grows Keith Alcorn / 12 November 2015 The US Food and Drug Administration has issued a warning that Viekira Pak and Technivie can cause “serious liver injury” mainly in patients with underlying advanced liver disease, following a small number of ... A more personalised approach to hepatitis C treatment may improve adherence and completion rates Roger Pebody / 09 March 2015 People receiving treatment for hepatitis C value clinicians who give information and clinical feedback that is personalised to their individual needs and lifestyle, and cite this as an important facilitator of good adherence. ... AbbVie 3D hepatitis C regimen is well-tolerated in phase 3 trials Liz Highleyman / 22 September 2014 AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference ... Low lymphocyte count a risk factor for infections for people taking HCV therapy Michael Carter / 15 January 2014 A low lymphocyte count is associated with an increased risk of infections during hepatitis C virus (HCV) treatment that includes pegylated interferon and ribavirin, according to the results of a large observational study ... Fear of future health problems encourage people to start and complete HCV therapy but concern about side-effects is a deterrent Michael Carter / 27 June 2013 US research has provided important insights into the factors that motivate and deter people from starting and completing therapy for hepatitis C virus (HCV) infection. Published in the online journal BMC Infectious Diseases, the ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive